MAP kinase activation (Homo sapiens)

From WikiPathways

Jump to: navigation, search
28, 40, 41, 4311, 32, 3911, 32, 4412, 13, 306, 10, 341, 4, 21, 25, 27...8, 1719, 30, 395, 1422, 20, 246, 8, 10, 342414, 176, 15, 237, 16, 35cytosolnucleoplasmp-S400,T290-MAP3K8 ADPMAP2K3,MAP2K6MAP2K3 UBB(1-76) MAPKAPK2 NFKB1(1-968) UBC(305-380) p-S218,S222-MAP2K1 FBXW11 p-T221,Y223-MAPK10 CUL1 p-S218,S222-MAP2K1,p-S257,T261-MAP2K4p-T222,S272,T334-MAPKAPK2 p-S189,T193-MAP2K3,p-S207,T211-MAP2K6TNIP2p-S927,S932-NFKB1(1-968) p-S257,T261-MAP2K4 ATPUBC(153-228) UBC(533-608) ADPMAPK8,9,10TNIP2 K63polyUb-TRAF6 p-T180,Y182-MAPK11 MAP2K4 ATPNOD2 ATPTNIP2 UBE2N TNIP2 p-S189,T193-MAP2K3,p-S207,T211-MAP2K6p-T180,Y182-MAPK11 p-T183,Y185-MAPK9 NFKB1:p-S400-MAP3K8:TNIP2p-S271,T275-MAP2K7 p38 MAPK:MAPKAPK2,3TNIP2 ADP3xUb-p-S927,S932-NFKB1(1-968) Ubp-S927,S932-NFKB1(1-968) p-S189,T193-MAP2K3 p-S927,S932-NFKB1(1-968):p-S,T-MAP3K8:TNIP2BTRC UBC(381-456) NFKB1:MAP3K8:TNIP2p-S400,T290-MAP3K8 ADPp-2S,S376,T,T209,T387-IRAK1 TAB1 MAPK9 MAP3K8IKBKG RPS27A(1-76) MAPK14 p-S257,T261-MAP2K4 MAP2K7,MAP2K4MAP3K8 TNIP2 UBC(77-152) NOD1 p-T180,Y182-MAPK11 TAB3 MAPKAPK2 p-p38MAPK:p-MAPKAPK2/3BTRC MAPK10 MAPKAPK3 UBC(609-684) p-MAPK8,9,10MAP2K1,MAP2K4MAPK targets/Nuclear eventsmediated by MAPkinasesSKP1 Activated TAKcomplexesp-S,2T-MAPKAPK3 CUL1 UBE2V1 ATPp-MAPK8,9,10p-p38 MAPK:MAPKAPK2,3IKBKG:p-S176,S180-CHUK:p-S177,S181-IKBKB3xUb,2xp-S-NFKB1(1-968):p-S,T-MAP3K8:TNIP2p-S400-MAP3K8 UBB(77-152) p-p38MAPK:p-S272,T222,T334-MAPKAPK2, p-S,2T-MAPKAPK3MAPKAPK3 (BTRC:CUL1:SKP1),(FBXW11:CUL1:SKP1)RAF-independentMAPK1/3 activationp-T180,Y182-MAPK14 ADPp-T221,Y223-MAPK10 MAP3K8 SKP1 UBC(1-76) MAP2K4 ATPiE-DAP p-S927,S932-NFKB1(1-968):MAP3K8:TNIP2NFKB1(1-968) p-T180,Y182-MAPK14 MAP3K8 MDP Ub-209-RIPK2 NFKB1(1-968)p-S177,S181-IKBKB TNIP2 TNIP2 K63polyUb NFKB1:p-T290-MAP3K8:TNIP23xUb-p-S927,S932-NFKB1(1-968)SCF-beta-TrCP1,2:p-S927,S932-NFKB1:p-S,T-MAP3K8:TNIP2IKBKG NFKB1(1-968) UBB(153-228) UBA52(1-76) p-T183,Y185-MAPK9 p-T180,Y182-MAPK14 MAPK11 p-MAP2K4/p-MAP2K7ATPUBC(457-532) p-S927,S932-NFKB1(1-968) p-S400,T290-MAP3K8 p-S207,T211-MAP2K6 MAP2K6 p-S176,S180-CHUK MAP3K7 ADPATPp-S,2T-MAPKAPK3 p-S189,T193-MAP2K3 p-IRAK2 UBC(229-304) p-S207,T211-MAP2K6 FBXW11 MAP2K1 p-T184,T187-MAP3K7 MAP2K7 p-T,Y-MAPK8 p-T,Y-MAPK8 p-S400,T290-MAP3K8p-S272,T222,T334-MAPKAPK2 MAPK8 ADPTAB2 9, 333118, 26, 423, 22, 3629


The mitogen activated protein kinase (MAPK) cascade, one of the most ancient and evolutionarily conserved signaling pathways, is involved in many processes of immune responses. The MAP kinases cascade transduces signals from the cell membrane to the nucleus in response to a wide range of stimuli (Chang and Karin, 2001; Johnson et al, 2002).

There are three major groups of MAP kinases

  • the extracellular signal-regulated protein kinases ERK1/2,
  • the p38 MAP kinase
  • and the c-Jun NH-terminal kinases JNK.
<p>ERK1 and ERK2 are activated in response to growth stimuli. Both JNKs and p38-MAPK are activated in response to a variety of cellular and environmental stresses. The MAP kinases are activated by dual phosphorylation of Thr and Tyr within the tripeptide motif Thr-Xaa-Tyr. The sequence of this tripeptide motif is different in each group of MAP kinases: ERK (Thr-Glu-Tyr); p38 (Thr-Gly-Tyr); and JNK (Thr-Pro-Tyr).<p>MAPK activation is mediated by signal transduction in the conserved three-tiered kinase cascade: MAPKKKK (MAP4K or MKKKK or MAPKKK Kinase) activates the MAPKKK. The MAPKKKs then phosphorylates a dual-specificity protein kinase MAPKK, which in turn phosphorylates the MAPK.<p>The dual specificity MAP kinase kinases (MAPKK or MKK) differ for each group of MAPK. The ERK MAP kinases are activated by the MKK1 and MKK2; the p38 MAP kinases are activated by MKK3, MKK4, and MKK6; and the JNK pathway is activated by MKK4 and MKK7. The ability of MAP kinase kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N-terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites.<p>The upstream signaling events in the TLR cascade that initiate and mediate the ERK signaling pathway remain unclear. View original pathway at:Reactome.</div>


Pathway is converted from Reactome ID: 450294
Reactome version: 66
Reactome Author 
Reactome Author: Shamovsky, Veronica

Quality Tags

Ontology Terms



View all...
  1. Lukas SM, Kroe RR, Wildeson J, Peet GW, Frego L, Davidson W, Ingraham RH, Pargellis CA, Labadia ME, Werneburg BG.; ''Catalysis and function of the p38 alpha.MK2a signaling complex.''; PubMed
  2. Cohen S, Achbert-Weiner H, Ciechanover A.; ''Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 Fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing.''; PubMed
  3. Arthur JS, Ley SC.; ''Mitogen-activated protein kinases in innate immunity.''; PubMed
  4. McLaughlin MM, Kumar S, McDonnell PC, Van Horn S, Lee JC, Livi GP, Young PR.; ''Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase.''; PubMed
  5. Meng W, Swenson LL, Fitzgibbon MJ, Hayakawa K, Ter Haar E, Behrens AE, Fulghum JR, Lippke JA.; ''Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export.''; PubMed
  6. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O, Akira S.; ''Essential function for the kinase TAK1 in innate and adaptive immune responses.''; PubMed
  7. Lutz C, Nimpf J, Jenny M, Boecklinger K, Enzinger C, Utermann G, Baier-Bitterlich G, Baier G.; ''Evidence of functional modulation of the MEKK/JNK/cJun signaling cascade by the low density lipoprotein receptor-related protein (LRP).''; PubMed
  8. Raingeaud J, Whitmarsh AJ, Barrett T, Dérijard B, Davis RJ.; ''MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway.''; PubMed
  9. Rothwarf DM, Zandi E, Natoli G, Karin M.; ''IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex.''; PubMed
  10. Thiefes A, Wolter S, Mushinski JF, Hoffmann E, Dittrich-Breiholz O, Graue N, Dörrie A, Schneider H, Wirth D, Luckow B, Resch K, Kracht M.; ''Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes.''; PubMed
  11. Stafford MJ, Morrice NA, Peggie MW, Cohen P.; ''Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62.''; PubMed
  12. Lang V, Symons A, Watton SJ, Janzen J, Soneji Y, Beinke S, Howell S, Ley SC.; ''ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability.''; PubMed
  13. Belich MP, Salmerón A, Johnston LH, Ley SC.; ''TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105.''; PubMed
  14. Ben-Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ.; ''Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2.''; PubMed
  15. Wang X, Nadarajah B, Robinson AC, McColl BW, Jin JW, Dajas-Bailador F, Boot-Handford RP, Tournier C.; ''Targeted deletion of the mitogen-activated protein kinase kinase 4 gene in the nervous system causes severe brain developmental defects and premature death.''; PubMed
  16. Mizukami Y, Yoshioka K, Morimoto S, Yoshida K.; ''A novel mechanism of JNK1 activation. Nuclear translocation and activation of JNK1 during ischemia and reperfusion.''; PubMed
  17. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ.; ''Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.''; PubMed
  18. Bogoyevitch MA, Kobe B.; ''Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.''; PubMed
  19. Waterfield MR, Zhang M, Norman LP, Sun SC.; ''NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase.''; PubMed
  20. Heissmeyer V, Krappmann D, Hatada EN, Scheidereit C.; ''Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha.''; PubMed
  21. Sithanandam G, Latif F, Duh FM, Bernal R, Smola U, Li H, Kuzmin I, Wixler V, Geil L, Shrestha S.; ''3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region.''; PubMed
  22. Gantke T, Sriskantharajah S, Ley SC.; ''Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase.''; PubMed
  23. Deacon K, Blank JL.; ''Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)/c-Jun NH2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3. MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo.''; PubMed
  24. Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, Salmeron A, Allen H, Hay RT, Ben-Neriah Y, Ley SC.; ''betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932.''; PubMed
  25. Clifton AD, Young PR, Cohen P.; ''A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress.''; PubMed
  26. Johnson GL, Lapadat R.; ''Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.''; PubMed
  27. Ben-Levy R, Leighton IA, Doza YN, Attwood P, Morrice N, Marshall CJ, Cohen P.; ''Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2.''; PubMed
  28. Chang L, Karin M.; ''Mammalian MAP kinase signalling cascades.''; PubMed
  29. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG.; ''Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation.''; PubMed
  30. Beinke S, Deka J, Lang V, Belich MP, Walker PA, Howell S, Smerdon SJ, Gamblin SJ, Ley SC.; ''NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity.''; PubMed
  31. Shi P, Zhu S, Lin Y, Liu Y, Liu Y, Chen Z, Shi Y, Qian Y.; ''Persistent stimulation with interleukin-17 desensitizes cells through SCFβ-TrCP-mediated degradation of Act1.''; PubMed
  32. Handoyo H, Stafford MJ, McManus E, Baltzis D, Peggie M, Cohen P.; ''IRAK1-independent pathways required for the interleukin-1-stimulated activation of the Tpl2 catalytic subunit and its dissociation from ABIN2.''; PubMed
  33. Krappmann D, Hatada EN, Tegethoff S, Li J, Klippel A, Giese K, Baeuerle PA, Scheidereit C.; ''The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component.''; PubMed
  34. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K.; ''Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction.''; PubMed
  35. Sundarrajan M, Boyle DL, Chabaud-Riou M, Hammaker D, Firestein GS.; ''Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK.''; PubMed
  36. Roskoski R.; ''ERK1/2 MAP kinases: structure, function, and regulation.''; PubMed
  37. ter Haar E, Prabhakar P, Liu X, Lepre C.; ''Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer.''; PubMed
  38. White A, Pargellis CA, Studts JM, Werneburg BG, Farmer BT.; ''Molecular basis of MAPK-activated protein kinase 2:p38 assembly.''; PubMed
  39. Roget K, Ben-Addi A, Mambole-Dema A, Gantke T, Yang HT, Janzen J, Morrice N, Abbott D, Ley SC.; ''IκB kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400.''; PubMed
  40. Dong C, Davis RJ, Flavell RA.; ''MAP kinases in the immune response.''; PubMed
  41. Bardwell AJ, Frankson E, Bardwell L.; ''Selectivity of docking sites in MAPK kinases.''; PubMed
  42. Yoon S, Seger R.; ''The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.''; PubMed
  43. Banerjee A, Gerondakis S.; ''Coordinating TLR-activated signaling pathways in cells of the immune system.''; PubMed
  44. Cho J, Melnick M, Solidakis GP, Tsichlis PN.; ''Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals.''; PubMed


View all...
101325view11:21, 1 November 2018ReactomeTeamreactome version 66
100862view20:53, 31 October 2018ReactomeTeamreactome version 65
100403view19:27, 31 October 2018ReactomeTeamreactome version 64
99951view16:12, 31 October 2018ReactomeTeamreactome version 63
99507view14:44, 31 October 2018ReactomeTeamreactome version 62 (2nd attempt)
99152view12:41, 31 October 2018ReactomeTeamreactome version 62
93984view13:49, 16 August 2017ReactomeTeamreactome version 61
93588view11:28, 9 August 2017ReactomeTeamreactome version 61
87875view12:14, 25 July 2016RyanmillerOntology Term : 'kinase mediated signaling pathway' added !
87874view12:13, 25 July 2016RyanmillerOntology Term : 'signaling pathway pertinent to immunity' added !
87873view12:12, 25 July 2016RyanmillerOntology Term : 'signaling pathway' added !
86696view09:24, 11 July 2016ReactomeTeamreactome version 56
83420view11:11, 18 November 2015ReactomeTeamVersion54
81623view13:10, 21 August 2015ReactomeTeamVersion53
78712view14:27, 18 January 2015EgonwRemoved @GroupRefs to a that didn't exist in the GPML.
77083view08:38, 17 July 2014ReactomeTeamFixed remaining interactions
76788view12:15, 16 July 2014ReactomeTeamFixed remaining interactions
76111view10:17, 11 June 2014ReactomeTeamRe-fixing comment source
75823view11:38, 10 June 2014ReactomeTeamReactome 48 Update
75173view14:12, 8 May 2014AnweshaFixing comment source for displaying WikiPathways description
74820view08:55, 30 April 2014ReactomeTeamNew pathway

External references


View all...
NameTypeDatabase referenceComment
(BTRC:CUL1:SKP1),(FBXW11:CUL1:SKP1)ComplexR-HSA-1168601 (Reactome)
3xUb, 2xp-S-NFKB1(1-968):p-S,T-MAP3K8:TNIP2ComplexR-HSA-5684242 (Reactome)
3xUb-p-S927,S932-NFKB1(1-968) ProteinP19838 (Uniprot-TrEMBL)
3xUb-p-S927,S932-NFKB1(1-968)ProteinP19838 (Uniprot-TrEMBL)
ADPMetaboliteCHEBI:16761 (ChEBI)
ATPMetaboliteCHEBI:15422 (ChEBI)
Activated TAK complexesComplexR-HSA-772536 (Reactome)
BTRC ProteinQ9Y297 (Uniprot-TrEMBL)
CUL1 ProteinQ13616 (Uniprot-TrEMBL)
FBXW11 ProteinQ9UKB1 (Uniprot-TrEMBL)
IKBKG ProteinQ9Y6K9 (Uniprot-TrEMBL)
IKBKG:p-S176,S180-CHUK:p-S177,S181-IKBKBComplexR-HSA-177663 (Reactome) Co-immunoprecipitation studies and size exclusion chromatography analysis indicate that the high molecular weight (around 700 to 900 kDa) IKK complex is composed of two kinase subunits (IKK1/CHUK/IKBKA and/or IKK2/IKBKB/IKKB) bound to a regulatory gamma subunit (IKBKG/NEMO) (Rothwarf DMet al. 1998; Krappmann D et al. 2000; Miller BS & Zandi E 2001). Variants of the IKK complex containing IKBKA or IKBKB homodimers associated with NEMO may also exist. Crystallographic and quantitative analyses of the binding interactions between N-terminal NEMO and C-terminal IKBKB fragments showed that IKBKB dimers would interact with NEMO dimers resulting in 2:2 stoichiometry (Rushe M et al. 2008). Chemical cross-linking and equilibrium sedimentation analyses of IKBKG (NEMO) suggest a tetrameric oligomerization (dimers of dimers) (Tegethoff S et al. 2003). The tetrameric NEMO could sequester four kinase molecules, yielding an 2xIKBKA:2xIKBKB:4xNEMO stoichiometry (Tegethoff S et al. 2003). The above data suggest that the core IKK complex consists of an IKBKA:IKBKB heterodimer associated with an IKBKG dimer or higher oligomeric assemblies. However, the exact stoichiometry of the IKK complex remains unclear.
K63polyUb R-HSA-450152 (Reactome)
K63polyUb-TRAF6 ProteinQ9Y4K3 (Uniprot-TrEMBL)
MAP2K1 ProteinQ02750 (Uniprot-TrEMBL)
MAP2K1,MAP2K4ComplexR-HSA-451647 (Reactome)
MAP2K3 ProteinP46734 (Uniprot-TrEMBL)
MAP2K3,MAP2K6ComplexR-HSA-167916 (Reactome)
MAP2K4 ProteinP45985 (Uniprot-TrEMBL)
MAP2K6 ProteinP52564 (Uniprot-TrEMBL)
MAP2K7 ProteinO14733 (Uniprot-TrEMBL)
MAP2K7,MAP2K4ComplexR-HSA-450305 (Reactome)
MAP3K7 ProteinO43318 (Uniprot-TrEMBL)
MAP3K8 ProteinP41279 (Uniprot-TrEMBL)
MAP3K8ProteinP41279 (Uniprot-TrEMBL)
MAPK targets/

Nuclear events mediated by MAP

PathwayR-HSA-450282 (Reactome) MAPKs are protein kinases that, once activated, phosphorylate their specific cytosolic or nuclear substrates at serine and/or threonine residues. Such phosphorylation events can either positively or negatively regulate substrate, and thus entire signaling cascade activity.

The major cytosolic target of activated ERKs are RSKs (90 kDa Ribosomal protein S6 Kinase). Active RSKs translocates to the nucleus and phosphorylates such factors as c-Fos(on Ser362), SRF (Serum Response Factor) at Ser103, and CREB (Cyclic AMP Response Element-Binding protein) at Ser133. In the nucleus activated ERKs phosphorylate many other targets such as MSKs (Mitogen- and Stress-activated protein kinases), MNK (MAP interacting kinase) and Elk1 (on Serine383 and Serine389). ERK can directly phosphorylate CREB and also AP-1 components c-Jun and c-Fos. Another important target of ERK is NF-KappaB. Recent studies reveals that nuclear pore proteins are direct substrates for ERK (Kosako H et al, 2009). Other ERK nuclear targets include c-Myc, HSF1 (Heat-Shock Factor-1), STAT1/3 (Signal Transducer and Activator of Transcription-1/3), and many more transcription factors.

Activated p38 MAPK is able to phosphorylate a variety of substrates, including transcription factors STAT1, p53, ATF2 (Activating transcription factor 2), MEF2 (Myocyte enhancer factor-2), protein kinases MSK1, MNK, MAPKAPK2/3, death/survival molecules (Bcl2, caspases), and cell cycle control factors (cyclin D1).

JNK, once activated, phosphorylates a range of nuclear substrates, including transcription factors Jun, ATF, Elk1, p53, STAT1/3 and many other factors. JNK has also been shown to directly phosphorylate many nuclear hormone receptors. For example, peroxisome proliferator-activated receptor 1 (PPAR-1) and retinoic acid receptors RXR and RAR are substrates for JNK. Other JNK targets are heterogeneous nuclear ribonucleoprotein K (hnRNP-K) and the Pol I-specific transcription factor TIF-IA, which regulates ribosome synthesis. Other adaptor and scaffold proteins have also been characterized as nonnuclear substrates of JNK.

MAPK10 ProteinP53779 (Uniprot-TrEMBL)
MAPK11 ProteinQ15759 (Uniprot-TrEMBL)
MAPK14 ProteinQ16539 (Uniprot-TrEMBL)
MAPK8 ProteinP45983 (Uniprot-TrEMBL)
MAPK8,9,10ComplexR-HSA-450289 (Reactome)
MAPK9 ProteinP45984 (Uniprot-TrEMBL)
MAPKAPK2 ProteinP49137 (Uniprot-TrEMBL)
MAPKAPK3 ProteinQ16644 (Uniprot-TrEMBL)
MDP MetaboliteCHEBI:59414 (ChEBI)
NFKB1(1-968) ProteinP19838 (Uniprot-TrEMBL)
NFKB1(1-968)ProteinP19838 (Uniprot-TrEMBL)
NFKB1:MAP3K8:TNIP2ComplexR-HSA-451638 (Reactome)
NFKB1:p-S400-MAP3K8:TNIP2ComplexR-HSA-5687880 (Reactome)
NFKB1:p-T290-MAP3K8:TNIP2ComplexR-HSA-5684265 (Reactome)
NOD1 ProteinQ9Y239 (Uniprot-TrEMBL)
NOD2 ProteinQ9HC29 (Uniprot-TrEMBL)
RAF-independent MAPK1/3 activationPathwayR-HSA-112409 (Reactome) Depending upon the stimulus and cell type mitogen-activated protein kinases (MAPK) signaling pathway can transmit signals to regulate many different biological processes by virtue of their ability to target multiple effector proteins (Kyriakis JM & Avruch J 2012; Yoon and Seger 2006; Shaul YD & Seger R 2007; Arthur JS & Ley SC 2013). In particular, the extracellular signal-regulated kinases MAPK3(ERK1) and MAPK1 (ERK2) are involved in diverse cellular processes such as proliferation, differentiation, regulation of inflammatory responses, cytoskeletal remodeling, cell motility and invasion through the increase of matrix metalloproteinase production (Viala E & Pouyssegur J 2004; Hsu MC et al. 2006; Dawson CW et al.2008; Kuriakose T et al. 2014).The canonical RAF:MAP2K:MAPK1/3 cascade is stimulated by various extracellular stimuli including hormones, cytokines, growth factors, heat shock and UV irradiation triggering the GEF-mediated activation of RAS at the plasma membrane and leading to the activation of the RAF MAP3 kinases. However, many physiological and pathological stimuli have been found to activate MAPK1/3 independently of RAF and RAS (Dawson CW et al. 2008; Wang J et al. 2009; Kuriakose T et al. 2014). For example, AMP-activated protein kinase (AMPK), but not RAF1, was reported to regulate MAP2K1/2 and MAPK1/3 (MEK and ERK) activation in rat hepatoma H4IIE and human erythroleukemia K562 cells in response to autophagy stimuli (Wang J et al. 2009). Tumor progression locus 2 (TPL2, also known as MAP3K8 and COT) is another MAP3 kinase which promotes MAPK1/3 (ERK)-regulated immune responses downstream of toll-like receptors (TLR), TNF receptor and IL1beta signaling pathways (Gantke T et al. 2011).

In response to stimuli the cell surface receptors transmit signals inducing MAP3 kinases, e.g., TPL2, MEKK1, which in turn phosphorylate MAP2Ks (MEK1/2). MAP2K then phosphorylate and activate the MAPK1/3 (ERK1 and ERK2 MAPKs). Activated MAPK1/3 phosphorylate and regulate the activities of an ever growing pool of substrates that are estimated to comprise over 160 proteins (Yoon and Seger 2006). The majority of ERK substrates are nuclear proteins, but others are found in the cytoplasm and other organelles. Activated MAPK1/3 can translocate to the nucleus, where they phosphorylate and regulate various transcription factors, such as Ets family transcription factors (e.g., ELK1), ultimately leading to changes in gene expression (Zuber J et al. 2000).

RPS27A(1-76) ProteinP62979 (Uniprot-TrEMBL)
SCF-beta-TrCP1,2:p-S927,S932-NFKB1:p-S,T-MAP3K8:TNIP2ComplexR-HSA-5684270 (Reactome)
SKP1 ProteinP63208 (Uniprot-TrEMBL)
TAB1 ProteinQ15750 (Uniprot-TrEMBL)
TAB2 ProteinQ9NYJ8 (Uniprot-TrEMBL)
TAB3 ProteinQ8N5C8 (Uniprot-TrEMBL)
TNIP2 ProteinQ8NFZ5 (Uniprot-TrEMBL)
TNIP2ProteinQ8NFZ5 (Uniprot-TrEMBL)
UBA52(1-76) ProteinP62987 (Uniprot-TrEMBL)
UBB(1-76) ProteinP0CG47 (Uniprot-TrEMBL)
UBB(153-228) ProteinP0CG47 (Uniprot-TrEMBL)
UBB(77-152) ProteinP0CG47 (Uniprot-TrEMBL)
UBC(1-76) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(153-228) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(229-304) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(305-380) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(381-456) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(457-532) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(533-608) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(609-684) ProteinP0CG48 (Uniprot-TrEMBL)
UBC(77-152) ProteinP0CG48 (Uniprot-TrEMBL)
UBE2N ProteinP61088 (Uniprot-TrEMBL)
UBE2V1 ProteinQ13404 (Uniprot-TrEMBL)
Ub-209-RIPK2 ProteinO43353 (Uniprot-TrEMBL)
UbComplexR-HSA-113595 (Reactome)
iE-DAP MetaboliteCHEBI:59271 (ChEBI)
p-2S,S376,T,T209,T387-IRAK1 ProteinP51617 (Uniprot-TrEMBL) This is the hyperphosphorylated, active form of IRAK1. The unknown coordinate phosphorylation events are to symbolize the multiple phosphorylations that likely take place in the ProST domain (aa10-211).
p-IRAK2 ProteinO43187 (Uniprot-TrEMBL)
p-MAP2K4/p-MAP2K7ComplexR-HSA-450299 (Reactome)
p-MAPK8,9,10ComplexR-HSA-450226 (Reactome)
p-MAPK8,9,10ComplexR-HSA-450253 (Reactome)
p-S,2T-MAPKAPK3 ProteinQ16644 (Uniprot-TrEMBL)
p-S176,S180-CHUK ProteinO15111 (Uniprot-TrEMBL)
p-S177,S181-IKBKB ProteinO14920 (Uniprot-TrEMBL)
p-S189,T193-MAP2K3 ProteinP46734 (Uniprot-TrEMBL)
p-S189,T193-MAP2K3, p-S207,T211-MAP2K6ComplexR-HSA-167984 (Reactome)
p-S189,T193-MAP2K3, p-S207,T211-MAP2K6ComplexR-HSA-450343 (Reactome)
p-S207,T211-MAP2K6 ProteinP52564 (Uniprot-TrEMBL)
p-S218,S222-MAP2K1 ProteinQ02750 (Uniprot-TrEMBL)
p-S218,S222-MAP2K1,p-S257,T261-MAP2K4ComplexR-HSA-451654 (Reactome)
p-S257,T261-MAP2K4 ProteinP45985 (Uniprot-TrEMBL)
p-S271,T275-MAP2K7 ProteinO14733 (Uniprot-TrEMBL)
p-S272,T222,T334-MAPKAPK2 ProteinP49137 (Uniprot-TrEMBL)
p-S400,T290-MAP3K8 ProteinP41279 (Uniprot-TrEMBL)
p-S400,T290-MAP3K8ProteinP41279 (Uniprot-TrEMBL)
p-S400-MAP3K8 ProteinP41279 (Uniprot-TrEMBL)
p-S927,S932-NFKB1(1-968) ProteinP19838 (Uniprot-TrEMBL)
p-S927,S932-NFKB1(1-968):MAP3K8:TNIP2ComplexR-HSA-5687885 (Reactome)
p-S927,S932-NFKB1(1-968):p-S,T-MAP3K8:TNIP2ComplexR-HSA-5684268 (Reactome)
p-T,Y-MAPK8 ProteinP45983 (Uniprot-TrEMBL)
p-T180,Y182-MAPK11 ProteinQ15759 (Uniprot-TrEMBL)
p-T180,Y182-MAPK14 ProteinQ16539 (Uniprot-TrEMBL)
p-T183,Y185-MAPK9 ProteinP45984 (Uniprot-TrEMBL)
p-T184,T187-MAP3K7 ProteinO43318 (Uniprot-TrEMBL)
p-T221,Y223-MAPK10 ProteinP53779 (Uniprot-TrEMBL)
p-T222,S272,T334-MAPKAPK2 ProteinP49137 (Uniprot-TrEMBL)


p-S272,T222,T334-MAPKAPK2, p-S,2T-MAPKAPK3
ComplexR-HSA-450241 (Reactome)
p-p38 MAPK:p-MAPKAPK2/3ComplexR-HSA-450254 (Reactome)
p-p38 MAPK: MAPKAPK2,3ComplexR-HSA-450213 (Reactome)
p38 MAPK:MAPKAPK2,3ComplexR-HSA-450269 (Reactome)

Annotated Interactions

View all...
SourceTargetTypeDatabase referenceComment
(BTRC:CUL1:SKP1),(FBXW11:CUL1:SKP1)ArrowR-HSA-5684250 (Reactome)
(BTRC:CUL1:SKP1),(FBXW11:CUL1:SKP1)R-HSA-5684248 (Reactome)
3xUb, 2xp-S-NFKB1(1-968):p-S,T-MAP3K8:TNIP2ArrowR-HSA-5684250 (Reactome)
3xUb, 2xp-S-NFKB1(1-968):p-S,T-MAP3K8:TNIP2R-HSA-5684273 (Reactome)
3xUb, 2xp-S-NFKB1(1-968):p-S,T-MAP3K8:TNIP2TBarR-HSA-451634 (Reactome)
3xUb-p-S927,S932-NFKB1(1-968)TBarR-HSA-451634 (Reactome)
ADPArrowR-HSA-168162 (Reactome)
ADPArrowR-HSA-450222 (Reactome)
ADPArrowR-HSA-450333 (Reactome)
ADPArrowR-HSA-450337 (Reactome)
ADPArrowR-HSA-450346 (Reactome)
ADPArrowR-HSA-451649 (Reactome)
ADPArrowR-HSA-5684261 (Reactome)
ADPArrowR-HSA-5684267 (Reactome)
ADPArrowR-HSA-5684275 (Reactome)
ATPR-HSA-168162 (Reactome)
ATPR-HSA-450222 (Reactome)
ATPR-HSA-450333 (Reactome)
ATPR-HSA-450337 (Reactome)
ATPR-HSA-450346 (Reactome)
ATPR-HSA-451649 (Reactome)
ATPR-HSA-5684261 (Reactome)
ATPR-HSA-5684267 (Reactome)
ATPR-HSA-5684275 (Reactome)
Activated TAK complexesmim-catalysisR-HSA-450337 (Reactome)
Activated TAK complexesmim-catalysisR-HSA-450346 (Reactome)
IKBKG:p-S176,S180-CHUK:p-S177,S181-IKBKBmim-catalysisR-HSA-5684267 (Reactome)
IKBKG:p-S176,S180-CHUK:p-S177,S181-IKBKBmim-catalysisR-HSA-5684275 (Reactome)
MAP2K1,MAP2K4R-HSA-451649 (Reactome)
MAP2K3,MAP2K6R-HSA-450346 (Reactome)
MAP2K7,MAP2K4R-HSA-450337 (Reactome)
MAP3K8R-HSA-451634 (Reactome)
MAPK8,9,10R-HSA-168162 (Reactome)
NFKB1(1-968)R-HSA-451634 (Reactome)
NFKB1:MAP3K8:TNIP2ArrowR-HSA-451634 (Reactome)
NFKB1:MAP3K8:TNIP2R-HSA-5684261 (Reactome)
NFKB1:MAP3K8:TNIP2R-HSA-5684267 (Reactome)
NFKB1:MAP3K8:TNIP2R-HSA-5684275 (Reactome)
NFKB1:p-S400-MAP3K8:TNIP2ArrowR-HSA-5684275 (Reactome)
NFKB1:p-T290-MAP3K8:TNIP2ArrowR-HSA-5684261 (Reactome)
R-HSA-168162 (Reactome) Activated human JNK kinases (MKK4 and MKK7) phosphorylate Thr183 and Tyr185 residues in the characteristic Thr-Pro-Tyr phosphoacceptor loop of each JNK.

JNK is differentially regulated by MKK4 and MKK7 depending on the stimulus. MKK7 is the primary activator of JNK in TNF, LPS, and PGN responses. However, TLR3 cascade requires both MKK4 and MKK7. Some studies reported that in three JNK isoforms tested MKK4 shows a striking preference for the tyrosine residue (Tyr-185), and MKK7 a striking preference for the threonine residue (Thr-183).

R-HSA-450222 (Reactome) Human p38 MAPK alpha forms a complex with MK2 even when the signaling pathway is not activated. This heterodimer is found mainly in the nucleus. The crystal structure of the unphosphorylated p38alpha-MK2 heterodimer was determined. The C-terminal regulatory domain of MK2 binds in the docking groove of p38 MAPK alpha, and the ATP-binding sites of both kinases are at the heterodimer interface (ter Haar et al. 2007).

Upon activation, p38 MAPK alpha activates MK2 by phosphorylating Thr-222, Ser-272, and Thr-334 (Ben-Levy et al. 1995).

The phosphorylation of MK2 at Thr-334 attenuates the affinity of the binary complex MK2:p38 alpha by an order of magnitude and leads to a large conformational change of an autoinhibitory domain in MK2. This conformational change unmasks not only the MK2 substrate-binding site but also the MK2 nuclear export signal (NES) thus leading to the MK2:p38 alpha translocation from the nucleus to the cytoplasm. Cytoplasmic active MK2 then phosphorylates downstream targets such as the heat-shock protein HSP27 and tristetraprolin (TTP) (Meng et al. 2002, Lukas et al. 2004, White et al. 2007).

MAPKAPK (MAPK-activated protein) kinase 3 (MK3, also known as 3pK) has been identified as the second p38 MAPK-activated kinase that is stimulated by different stresses (McLaughlin et al. 1996; Sithanandam et al. 1996; reviewed in Gaestel 2006). MK3 shows 75% sequence identity to MK2 and, like MK2, is activated by p38 MAPK alpha and p38 MAPK beta. MK3 phosphorylates peptide substrates with kinetic constants similar to MK2 and phosphorylates the same serine residues in HSP27 at the same relative rates as MK2 (Clifton et al. 1996) indicating an identical phosphorylation-site consensus sequence. Hence, it is assumed that its substrate spectrum is either identical to or at least overlapping with MK2.

R-HSA-450257 (Reactome) p38 MAPK alpha does not have a nuclear export signal (NES) and cannot leave the nucleus by itself, but rather needs to be associated with MAP kinase-activated protein kinase 2 (MAPKAPK2 or MK2). The NES of MAPKAPK2 facilitates the transport of both kinases from the nucleus to the cytoplasm but only after MK2 has been phosphorylated by p38alpha.

p38 MAPK alpha phosphorylates MK2 at Thr222, Ser272, and Thr334. The phosphorylation of Thr334 but not the kinase activity of MK2 has been demonstrated to be critical for the nuclear export of the p38 alpha - MK2 complex. Phosphorylation of Thr334 is believed to induce a conformational change in the complex exposing NES prior to interaction with the leptomycin B-sensitive nuclear export receptor.

R-HSA-450296 (Reactome) The p38 activators MKK3 (MAP2K3) and MKK6 (MAP2K6) were present in both the nucleus and the cytoplasm, consistent with a role in activating p38 in the nucleus.
R-HSA-450333 (Reactome) The MAPK level components of this cascade are p38MAPK-alpha, -beta, -gamma and -sigma. All of those isoforms are activated by phosphorylation of the Thr and Tyr in the Thr-Gly-Tyr motif in their activation loops.
R-HSA-450337 (Reactome) In human, phosphorylation of MKK4 (MAP2K4) and MKK7 (MAP2K7) by TAK1 occurs at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loops.

Residues involved in activation of these protein kinases correspond to human Ser271, Thr275 in MKK7 and Ser257, Thr261 in MKK4.

Cell lines lacking MKK4 exhibit defective activation of JNK and AP-1 dependent transcription activity in response to some cellular stresses; JNK and p38 MAPK activities were decreased by around 80% and 20%, respectively, following deletion of the mkk4 gene.

R-HSA-450346 (Reactome) Human MKK3 (MAP2K4) and MKK6 (MAP2K6) are two closely related dual-specificity protein kinases. Both are activated by cellular stress and inflammatory cytokines, and both phosphorylate and activate p38 MAP kinase at its activation site Thr-Gly-Tyr but do not phosphorylate or activate Erk1/2 or SAPK/JNK.

Activation of MKK3 and MKK6 occurs through phosphorylation of serine and threonine residues at the typical Ser-Xaa-Ala-Xaa-Thr motif in their activation loop. Residues involved into these protein kinases activation correspond to human sites Ser189 and Thr193 for MKK3 and Ser207 and Thr211 for MKK6 .

R-HSA-450348 (Reactome) c-Jun NH2 terminal kinase (JNK) plays a role in conveying signals from the cytosol to the nucleus, where they associate and activate their target transcription factors.
R-HSA-451634 (Reactome) The C-terminal half of NFKB1 p105 forms a high-affinity stoichiometric association with MAP3K8 (TPL2) via two distinct interactions (Belich et al. 1999; Beinke et al. 2003). The Tpl2 C-terminus (residues 398-467) binds to a region N-terminal to the p105 ankyrin repeat region (human p105 residues 497-534), whereas the Tpl2 kinase domain interacts with the p105 death domain (Beinke et al. 2003). In unstimulated macrophages, all detectable Tpl2 is associated with p105 (Belich et al. 1999; Lang et al. 2004). Binding to p105 maintains the stability of Tpl2 but inhibits Tpl2 MEK kinase activity by preventing access to MEK (Beinke et al. 2003; Waterfield et al. 2003). Tpl2 phosphorylation at Thr-290 may also play a role in the activation of Tpl2 (Cho & Tsichlis 2005).

A20-binding inhibitor of NFkappaB2 (ABIN-2 ot TNIP2) interacts with Tpl2 and p105 but preferentially forms a ternary complex with both proteins. As ABIN2 is a polyubiquitin binding protein, it has been suggested that it may facilitate recruitment of the p105/Tpl2 complex to the activated IKK complex, allowing IKK2 induced p105 phosphorylation and consequent Tpl2 activation.

R-HSA-451649 (Reactome) Tpl2 (also known as Cot, officially known as MAP3K8) is constitutively bound to NFKB p105 (p105) which inhibits its MEK kinase activity in resting cells. Proteolysis of p105 frees Tpl2 from p105 and allows subsequent phosphorylation and activation of MEK1. Tpl2 can also activate SEK1 (MAP2K4). Phosphorylation of Tpl-2 is believed to play a role in its activation (Cho et al, 2005; Robinson et al. 2007).
Positions of phosphorylations represented here are inferred from general experimental data (Zheng & Guan, 1994).
R-HSA-5684248 (Reactome) IKK-mediated NFkB p105 phosphorylation generates a binding site for betaTrCP, the receptor subunit of the SCF-type beta-TrCP ubiquitin E3 ligase complex.
R-HSA-5684250 (Reactome) Beta-TrCP ubiquitinates p105 at several lysine residues within the C-terminal region 660-968. The level of ubiquitination is variable; in this reaction p105 is represented with 3 ubiquitinated lysine residues. Removal of all lysines within this region abolishes subsequent p105 degradation.
R-HSA-5684261 (Reactome) The activity of tumor progression locus-2 (TPL2, also known as COT and MAP3K8) is regulated by means of phosphorylation (Gantke T 2011).

The catalytic subunit of MAP3K8 (TPL2) was reported to undergo phosphorylation at Thr290 in human embryonic kidney 293 (HEK293) cells transfected with MAP3K8 (Luciano BS et al. 2004; Cho J et al. 2005; Stafford MJ et al. 2006). Mutation of this residue to alanine prevented the LPS-stimulated activation of MAP3K8 in mouse macrophages (Cho J et al. 2005). Experiments with a small-molecule inhibitor of MAP3K8 have suggested that Thr290 is autophosphosphorylated after IL-1 beta stimulation of IL-1R-expressing HEK293T cells (Handoyo H et al. 2009). However, a catalytically inactive mutant of MAP3K8 (Tpl2-K167M) was reported to become phosphorylated at Thr290 in transfected HEK-293 cells, suggesting that Thr290 phosphorylation did not occur as a result of autophosphorylation (Cho J et al. 2005) In addition, the phosphorylation at Thr290 was also reported to be catalysed by IKBKB, based on small interfering RNA(siRNA)-knockdown studies and the use of high concentrations of the IKBKB inhibitor PS1145 (Cho J et al. 2005). However, the other work showed that lower concentrations of PS1145, but nevertheless sufficient to completely inhibit IKBKB, did not affect the IL-1-stimulated phosphorylation of transfected MAP3K8 at Thr290, suggesting that the IL-1 beta stimulated phosphorylation of Thr290 is catalysed by a protein kinase distinct from IKBKB. (Stafford MJ et al. 2006). Thus, phosphorylation at Thr290 is required for the physiological activation of MAP3K8 by external signals, although the mode of the modification remains to be clarified.

Activation of MAP3K8 may also occur trough phosphorylation on Ser62 and Ser400 (Stafford MJ et al. 2006; Roget K et al. 2012).

R-HSA-5684267 (Reactome) NFkappaB p105 protein (p105) is a precursor of the NFkappaB p50 subunit and an inhibitor of NFkappaB. The IkappaB kinase (IKK) complex phosphorylates p105 on S927 within the PEST region. TNF-alpha-induced p105 proteolysis additionally requires the phosphorylation of S932. Purified IKK (IKK1) or IKKB (IKK2) can phosphorylate both these regulatory serines in vitro.
R-HSA-5684273 (Reactome) IKBKB-induced proteolysis of NFkB p105 to p50 releases MAP3K8 (TPL2) from the complex with NFkB p105 and ABIN2. On TLR or IL1beta stimulation, dissociated MAP3K8 with an adequate phosphorylation state activates MAP2K (MKK1/2) and consequently MAPK1/3 (ERK1/2).
R-HSA-5684275 (Reactome) The activity of tumor progression locus-2 (TPL2, also known as COT and MAP3K8) is regulated by means of phosphorylation. MAP3K8 undergoes phosphorylated on S400 in its C-terminal tail to activate MAP2Ks (MEK1/2) following LPS stimulation of macrophages. Different experimental systems have suggested that S400 is either autophosphosphorylated by MAPK3P8 (IL-1?-stimulated IL-1R-293T cells) or transphosphorylated by an unknown kinase (LPS-stimulated RAW264.7 macrophages).
SCF-beta-TrCP1,2:p-S927,S932-NFKB1:p-S,T-MAP3K8:TNIP2ArrowR-HSA-5684248 (Reactome)
SCF-beta-TrCP1,2:p-S927,S932-NFKB1:p-S,T-MAP3K8:TNIP2R-HSA-5684250 (Reactome)
SCF-beta-TrCP1,2:p-S927,S932-NFKB1:p-S,T-MAP3K8:TNIP2mim-catalysisR-HSA-5684250 (Reactome)
TNIP2ArrowR-HSA-5684273 (Reactome)
TNIP2R-HSA-451634 (Reactome)
UbArrowR-HSA-5684273 (Reactome)
UbR-HSA-5684250 (Reactome)
p-MAP2K4/p-MAP2K7ArrowR-HSA-450337 (Reactome)
p-MAP2K4/p-MAP2K7mim-catalysisR-HSA-168162 (Reactome)
p-MAPK8,9,10ArrowR-HSA-168162 (Reactome)
p-MAPK8,9,10ArrowR-HSA-450348 (Reactome)
p-MAPK8,9,10R-HSA-450348 (Reactome)
p-S189,T193-MAP2K3, p-S207,T211-MAP2K6ArrowR-HSA-450296 (Reactome)
p-S189,T193-MAP2K3, p-S207,T211-MAP2K6ArrowR-HSA-450346 (Reactome)
p-S189,T193-MAP2K3, p-S207,T211-MAP2K6R-HSA-450296 (Reactome)
p-S189,T193-MAP2K3, p-S207,T211-MAP2K6mim-catalysisR-HSA-450333 (Reactome)
p-S218,S222-MAP2K1,p-S257,T261-MAP2K4ArrowR-HSA-451649 (Reactome)
p-S400,T290-MAP3K8ArrowR-HSA-5684273 (Reactome)
p-S400,T290-MAP3K8mim-catalysisR-HSA-451649 (Reactome)
p-S927,S932-NFKB1(1-968):MAP3K8:TNIP2ArrowR-HSA-5684267 (Reactome)
p-S927,S932-NFKB1(1-968):p-S,T-MAP3K8:TNIP2R-HSA-5684248 (Reactome)


p-S272,T222,T334-MAPKAPK2, p-S,2T-MAPKAPK3
ArrowR-HSA-450257 (Reactome)
p-p38 MAPK:p-MAPKAPK2/3ArrowR-HSA-450222 (Reactome)
p-p38 MAPK:p-MAPKAPK2/3R-HSA-450257 (Reactome)
p-p38 MAPK: MAPKAPK2,3ArrowR-HSA-450333 (Reactome)
p-p38 MAPK: MAPKAPK2,3R-HSA-450222 (Reactome)
p-p38 MAPK: MAPKAPK2,3mim-catalysisR-HSA-450222 (Reactome)
p38 MAPK:MAPKAPK2,3R-HSA-450333 (Reactome)

Personal tools